Patents by Inventor Lincoln V. Johnson

Lincoln V. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200077641
    Abstract: Disclosed herein are methods and compositions for the identification of viability enhancing cell features and substrate features as they relate to post-cryopreservation survival of substrate seeded cells. Embodiments of the present invention further involve identification of cell features to manufacture a supernatant that is useful for cell culturing and treatment of various diseases.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 12, 2020
    Applicants: University of Southern California, The Regents of the University of California
    Inventors: Britney O. Pennington, Jeffrey K. Bailey, Mohamed A. Faynus, Cassidy Arnold, Lincoln V. Johnson, Dennis O. Clegg, Mark S. Humayun, David R. Hinton, Danhong Zhu, Debbie Mitra
  • Patent number: 10246682
    Abstract: The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: April 2, 2019
    Assignees: The Regents of the University of California, University of Southern California
    Inventors: Dennis Clegg, Sherry T. Hikita, Lincoln V. Johnson, Liane Miller, Marlene Tsie, Chelsea D. Presbrey, Lisa R. Conti, Michelle A. Maloney, David R. Hinton, Qirui Hu
  • Patent number: 8808687
    Abstract: Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: August 19, 2014
    Inventors: Mark Humayun, Ashish Ahuja, Yu-Chong Tai, David Hinton, Robert Grubbs, Dennis Clegg, Lincoln V. Johnson, Sherry T. Hikita
  • Patent number: 7511009
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: March 31, 2009
    Assignee: The National Institutes of Health
    Inventors: Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
  • Patent number: 7179621
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Grant
    Filed: August 1, 2000
    Date of Patent: February 20, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gerald J. Chader, Ignacio R. Rodriguez, Joyce Tombran-Tink, Sofia Patricia Becerra, Fintan R. Steele, Lincoln V. Johnson
  • Publication number: 20030096750
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule.
    Type: Application
    Filed: August 9, 2002
    Publication date: May 22, 2003
    Inventors: Joyce Tombran-Tink, Fintan R. Steele, Gerald J. Chader, Sofia Patricia Becerra, Lincoln V. Johnson, Ignacio R. Rodriguez
  • Patent number: 6451763
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: September 17, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
  • Patent number: 6319687
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: November 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gerald J. Chader, S. Patricia Becerra, Joyce Tombran-Tink, Lincoln V. Johnson, Fintan R. Steele, Ignacio Rodriguez
  • Patent number: 5409760
    Abstract: Camouflage materials that are highly visible to humans but inconspicuous to dichromatic animals are provided. The camouflage materials emit, or simulate emission, of light at or about the neutral point of a dichromatic animal. One kind of camouflage material contains a coloring agent, which limits photopic light emissions from the material to occur at or about the neutral point. Another kind of camouflage material contains at least two coloring agents, which limit photopic light emissions to at least two bands of wavelengths. The respective proportions and spectral properties of these coloring agents are chosen so that the combination of photopic light emitted by camouflage materials incorporating them simulates the appearance of monochromatic light at or about the neutral point.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: April 25, 1995
    Assignee: Ocutech, Inc.
    Inventors: Jay Neitz, Don H. Anderson, Lincoln V. Johnson, Gregory S. Hageman